Clarimedix announced that Johnson & Johnson Corporate Office of Science and Technology (COSAT) has secured an investment for a human proof-of-concept study to determine the viability of Clarimedix’s product for cerebral vasospasm. The study will be completed by the end of the second quarter of 2012, at which point the company anticipates closing a further round of investment from an investor syndicate.
“We are delighted to have the investment from the Johnson & Johnson COSAT as we secure validation of Clarimedix’s proprietary technology,” said John Dunning, CEO of Clarimedix. “Researchers understand there are a wide variety of conditions impacted by underlying vascular dysfunction and our approach may offer the first safe, effective nitric oxide (NO) treatment for patients with these hard-to-treat conditions.”
Clarimedix has developed a powerful nitric oxide donor alternative with a safety profile that for the first time will enable widespread, safe treatment of a variety of conditions including cerebral vasospasm, Raynaud’s phenomenon, and Alzheimer’s disease. This technology is a non-invasive, light-based medical device in the form of a light emitting diode (LED) patch that is applied over the skin to trigger local, controllable and safe nitric oxide production. As a result, blood flow is increased, vasoconstriction and inflammation are reduced and oxygen delivery to areas that have been deprived improves.